Palbociclib
CAS 571190-30-2
Overview
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy
Anant Labs manufacture and furnish high quality Palbociclib impurities for global markets. Our Palbociclib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.

















